Scott J Pilla, Isabelle J Wang, Olive Tang, Nancy L Schoenborn, Cynthia M Boyd, Michael P Bancks, Nestoras N Mathioudakis, Nisa M Maruthur
{"title":"A National Physician Survey Examining Switching From Sulfonylureas or Insulin to Newer Diabetes Medications.","authors":"Scott J Pilla, Isabelle J Wang, Olive Tang, Nancy L Schoenborn, Cynthia M Boyd, Michael P Bancks, Nestoras N Mathioudakis, Nisa M Maruthur","doi":"10.2337/cd24-0043","DOIUrl":null,"url":null,"abstract":"<p><p>This study was a national survey of U.S. physicians in general medicine, geriatrics, or endocrinology who were asked what medication change they would make for adults with type 2 diabetes taking sulfonylureas or insulin with an A1C below their individualized goal. Responding physicians switched the hypoglycemia-causing medication a median of 4 times (interquartile range 1-9) among 27 opportunities and selected dipeptidyl peptidase 4 inhibitors most often when switching. Sodium-glucose cotransporter 2 inhibitors were selected less frequently, including when indicated for cardiovascular and renal comorbidities, but significantly more often among physicians caring for a greater proportion of patients with private health insurance. Overcoming barriers to switching hypoglycemia-causing medications may help to reduce rates of hypoglycemia while targeting cardiovascular and renal comorbidities.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 1","pages":"33-42"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739336/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/cd24-0043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
This study was a national survey of U.S. physicians in general medicine, geriatrics, or endocrinology who were asked what medication change they would make for adults with type 2 diabetes taking sulfonylureas or insulin with an A1C below their individualized goal. Responding physicians switched the hypoglycemia-causing medication a median of 4 times (interquartile range 1-9) among 27 opportunities and selected dipeptidyl peptidase 4 inhibitors most often when switching. Sodium-glucose cotransporter 2 inhibitors were selected less frequently, including when indicated for cardiovascular and renal comorbidities, but significantly more often among physicians caring for a greater proportion of patients with private health insurance. Overcoming barriers to switching hypoglycemia-causing medications may help to reduce rates of hypoglycemia while targeting cardiovascular and renal comorbidities.
期刊介绍：
The mission of Clinical Diabetes is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. Clinical Diabetes is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
